GB18-06, a nanobody targeting GDF15, effectively alleviates weight loss and restores physical function in cachexia models.

ABSTRACT: Cachexia is a complicated metabolic syndrome mainly associated with cancers, characterized by extreme weight loss and muscle wasting. It is a debilitating condition that negatively affects prognosis and survival. However, there is currently no effective pharmacological intervention that can reverse body weight loss and improve physical performance in patients with cachexia. Growth differentiation factor 15 (GDF15) can suppress appetite and regulate energy balance through binding to glial cell-derived neurotrophic factor receptor alpha-like (GFRAL). In order to develop a novel, effective treatment for cachexia, we generated a GDF15-targeting VHH nanobody, GB18-06, that was able to bind GDF15 with high affinity. In vitro, GB18-06 potently inhibited the GDF15-GFRAL signaling pathway, l

SUBMITTER: Huang Y 

PROVIDER: S-EPMC11485916 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature